209 related articles for article (PubMed ID: 28293834)
1. Synthesis and evaluation of novel HCV replication inhibitors.
McGowan DC; Khamlichi MD; De Groot A; Pauwels F; Delouvroy F; Van Emelen K; Simmen K; Raboisson P
Mol Divers; 2017 May; 21(2):475-481. PubMed ID: 28293834
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
3. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
Gao M
Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
[TBL] [Abstract][Full Text] [Related]
5. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
[TBL] [Abstract][Full Text] [Related]
6. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective synthesis and biological evaluations of novel 3'-deoxy-4'-azaribonucleosides as inhibitors of hepatitis C virus RNA replication.
Chiacchio U; Borrello L; Crispino L; Rescifina A; Merino P; Macchi B; Balestrieri E; Mastino A; Piperno A; Romeo G
J Med Chem; 2009 Jul; 52(13):4054-7. PubMed ID: 19419173
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.
Boucle S; Tao S; Amblard F; Stanton RA; Nettles JH; Li C; McBrayer TR; Whitaker T; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2015 Sep; 25(17):3711-5. PubMed ID: 26099532
[TBL] [Abstract][Full Text] [Related]
9. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
Amblard F; Zhang H; Zhou L; Shi J; Bobeck DR; Nettles JH; Chavre S; McBrayer TR; Tharnish P; Whitaker T; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2013 Apr; 23(7):2031-4. PubMed ID: 23466233
[TBL] [Abstract][Full Text] [Related]
11. NS5A inhibitors for the treatment of hepatitis C infection.
Gitto S; Gamal N; Andreone P
J Viral Hepat; 2017 Mar; 24(3):180-186. PubMed ID: 27925362
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors.
Shi J; Zhou L; Amblard F; Bobeck DR; Zhang H; Liu P; Bondada L; McBrayer TR; Tharnish PM; Whitaker T; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2012 May; 22(10):3488-91. PubMed ID: 22507961
[TBL] [Abstract][Full Text] [Related]
13. Identification of hepatitis C virus NS5A inhibitors.
Lemm JA; O'Boyle D; Liu M; Nower PT; Colonno R; Deshpande MS; Snyder LB; Martin SW; St Laurent DR; Serrano-Wu MH; Romine JL; Meanwell NA; Gao M
J Virol; 2010 Jan; 84(1):482-91. PubMed ID: 19812153
[TBL] [Abstract][Full Text] [Related]
14. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis C virus infection by NS5A-specific aptamer.
Yu X; Gao Y; Xue B; Wang X; Yang D; Qin Y; Yu R; Liu N; Xu L; Fang X; Zhu H
Antiviral Res; 2014 Jun; 106():116-24. PubMed ID: 24713119
[TBL] [Abstract][Full Text] [Related]
16. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
Klumpp K; Lévêque V; Le Pogam S; Ma H; Jiang WR; Kang H; Granycome C; Singer M; Laxton C; Hang JQ; Sarma K; Smith DB; Heindl D; Hobbs CJ; Merrett JH; Symons J; Cammack N; Martin JA; Devos R; Nájera I
J Biol Chem; 2006 Feb; 281(7):3793-9. PubMed ID: 16316989
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent macrocyclic HCV NS5A inhibitors.
Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
[TBL] [Abstract][Full Text] [Related]
19. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Lee C
Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
[TBL] [Abstract][Full Text] [Related]
20. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
